|
|
Home
Search
Study Topics
Glossary
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||
| Tracking Information | |
|---|---|
| First Received Date ICMJE | December 3, 2002 |
| Last Updated Date | March 31, 2006 |
| Start Date ICMJE | |
| Primary Completion Date | |
| Current Primary Outcome Measures ICMJE | |
| Original Primary Outcome Measures ICMJE | |
| Change History | Complete list of historical versions of study NCT00050297 on ClinicalTrials.gov Archive Site |
| Current Secondary Outcome Measures ICMJE | |
| Original Secondary Outcome Measures ICMJE | |
| Descriptive Information | |
| Brief Title ICMJE | YM598 in Patients With Rising PSA After Initial Therapy for Localized Prostate Cancer |
| Official Title ICMJE | |
| Brief Summary | The purpose of this study is to determine the optimal dosage of YM598 for slowing down disease progression in patients with rising PSA after initial therapy for localized prostate cancer. |
| Detailed Description | |
| Study Phase | Phase II |
| Study Type ICMJE | Interventional |
| Study Design ICMJE | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study |
| Condition ICMJE | Prostate Cancer |
| Intervention ICMJE | Drug: YM598 |
| Study Arms / Comparison Groups | |
| Publications * | |
|
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline. |
|
| Recruitment Information | |
| Recruitment Status ICMJE | Terminated |
| Enrollment ICMJE | |
| Completion Date | |
| Primary Completion Date | |
| Eligibility Criteria ICMJE | |
| Gender | Male |
| Ages | 18 Years and older |
| Accepts Healthy Volunteers | No |
| Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects |
| Location Countries ICMJE | Belgium, Czech Republic, France, Germany, Poland, Spain, United Kingdom |
| Administrative Information | |
| NCT ID ICMJE | NCT00050297 |
| Responsible Party | |
| Study ID Numbers ICMJE | 598-CL-004 |
| Study Sponsor ICMJE | Astellas Pharma Inc |
| Collaborators ICMJE | Astellas Pharma US, Inc. |
| Investigators ICMJE | |
| Information Provided By | Astellas Pharma Inc |
| Verification Date | March 2006 |
|
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |
|
